^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
CANCER:

Differentiated Thyroid Carcinoma

2d
Prognostic factors evaluated in differentiated thyroid carcinomas. (PubMed, Endocr Connect)
Dynamic markers, such as thyroglobulin doubling rate, metastatic tumor volume-doubling rate, and immunological indicators, such as the neutrophil-to-lymphocyte ratio, are useful for predicting the prognosis and evaluating the effectiveness of treatments, such as radioactive iodine therapy and molecular targeted therapy for recurrent lesions. Clinicians should accurately evaluate the prognostic markers of PTC and FTC in the pre-, intra-, and postoperative phases.
Journal
|
TERT (Telomerase Reverse Transcriptase)
2d
Engineered hUCMSC-derived extracellular vesicles deliver circ-0000258 to restore p53-mediated tumor suppression in papillary thyroid carcinoma. (PubMed, BMC Cancer)
This study has established the circ-0000258/miR-146b/p53 regulatory axis as a crucial mechanism underlying tumor suppression in PTC. It has also demonstrated the translational potential of hUCMSC-EVs as a safe and efficient delivery vehicle. By integrating the functional role of circ-0000258 with the targeted delivery advantages of engineered EVs, this research not only provides a novel strategy for the targeted treatment of thyroid cancer but also offers a theoretical basis and technical paradigm for the development of novel anti-tumor biological agents. It is anticipated to advance the field of precision oncology to a new level.
Journal
|
MIR146B (MicroRNA 146b)
|
cisplatin
3d
Study on the anti-tumor effect of Wall-broken ganoderma lucidum spore powder on papillary thyroid cancer. (PubMed, Sci Rep)
In vivo, BGLSP reduced tumor growth and Ki-67 expression, consistent with in vitro findings. These findings demonstrate that BGLSP exerts anti-tumor effects in PTC by targeting proliferation, apoptosis, and EMT, supporting its traditional use and suggesting potential as a natural adjuvant therapy worthy of further studies.
Journal
|
CDH1 (Cadherin 1) • CASP3 (Caspase 3) • VIM (Vimentin) • CASP8 (Caspase 8) • CDH2 (Cadherin 2) • TJP1 (Tight Junction Protein 1) • ZEB1 (Zinc Finger E-box Binding Homeobox 1)
6d
Recent developments in eosinophilic renal neoplasms: what's new, true and important? (PubMed, Histopathology)
The recent developments and acquired knowledge on newer renal entities with eosinophilic cytoplasm opened insights into the clinical, pathological, immunohistochemical, molecular, epidemiological aspects, and the prognosis of these entities. We emphasize the role of routine morphology, aided by appropriate and select immunohistochemistry, as essential keys for diagnosing eosinophilic renal tumours.
Review • Journal
|
ALK (Anaplastic lymphoma kinase) • FH (Fumarate Hydratase) • TFE3 (Transcription Factor Binding To IGHM Enhancer 3) • FLCN (Folliculin) • TFEB (Transcription Factor EB 2)
|
ALK rearrangement
6d
Assessing patient risk, benefit, and outcomes in drug development: a decade of vemurafenib clinical trials. (PubMed, Melanoma Manag)
Although vemurafenib showed efficacy in metastatic melanoma, off-label use resulted in limited benefit and increased adverse events. Unclear endpoints and underreported adverse events highlight the need for improved clinical trial design.
Journal
|
BRAF (B-raf proto-oncogene)
|
BRAF mutation
|
Zelboraf (vemurafenib)
6d
SG04 Early-onset superficial spreading melanoma and macrocephaly: think Cowden syndrome. (PubMed, Br J Dermatol)
In the literature, Cowden syndrome has been associated with breast cancer, thyroid cancer, endometrial cancer and a very small percentage of melanomas. However, this is the first report of Cowden syndrome that has been diagnosed after an early-onset superficial spreading melanoma.
Journal • BRCA Biomarker
|
BRCA2 (Breast cancer 2, early onset) • PTEN (Phosphatase and tensin homolog) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • BAP1 (BRCA1 Associated Protein 1) • CDK4 (Cyclin-dependent kinase 4) • POT1 (Protection of telomeres 1)
|
PTEN mutation
7d
An Interpretable Machine Learning Model for Predicting Occult Central Lymph Node Metastasis in Papillary Thyroid Cancer. (PubMed, J Clin Endocrinol Metab)
This is the first study to identify RET fusion positivity as an independent OLNM risk factor in cN0 PTC. The developed RF model demonstrates moderate predictive performance for OLNM risk and provides a framework for integrating clinical, sonographic, and molecular data, and is deployed as a web calculator (https://predictingoccultlymphnodemetastasis.shinyapps.io/web3/).
Journal
|
BRAF (B-raf proto-oncogene) • RET (Ret Proto-Oncogene)
|
BRAF mutation • RET fusion
7d
The diagnostic efficacy of serum galectin-3 and other markers in papillary thyroid carcinoma. (PubMed, Gland Surg)
When two markers were combined, the AUC increased to 0.785 (sensitivity 70.6% and specificity 87.4%; P<0.001). Our results suggest that the combination of serum GAL-3 and Ki-67 may serve as a useful adjunct to existing diagnostic methods of thyroid cancer, such as ultrasonography and fine-needle aspiration biopsy (FNAB).
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • NCAM1 (Neural cell adhesion molecule 1) • LGALS3 (Galectin 3) • KRT19 (Keratin 19)
7d
Genomic Characterization of Papillary Thyroid Carcinoma: Age Differences in Tumor Aggressiveness and Immune Infiltration. (PubMed, Diagnostics (Basel))
These findings support evaluation of translational strategies, such as CXCR4 inhibition, restoration of antigen presentation, and macrophage reprogramming, to convert "cold" tumors into immune-permissive lesions. Validation in larger, prospective, multicenter cohorts is required.
Journal
|
CXCR4 (Chemokine (C-X-C motif) receptor 4) • HLA-DRA (Major Histocompatibility Complex, Class II, DR Alpha) • IL1B (Interleukin 1, beta)
8d
PREVALENCE OF THE BRAF V600E MUTATION AMONG INDIGENOUS INDIVIDUALS WITH PAPILLARY THYROID CARCINOMA RESIDING IN A RADIATION-EXPOSED AREA. (PubMed, Georgian Med News)
The analysis revealed an association between the BRAF V600E mutation and papillary thyroid cancer in patients exposed to radiation from nuclear testing at the former SNTS. These findings offer new prospects for targeted therapy and early diagnosis of malignant thyroid neoplasms. Following the closure of the test site, positive developments in public health have been observed: radiophobia has decreased and the population's quality of life has improved. Furthermore, the adoption of iodine prophylaxis legislation and the country's industrial growth have contributed to improved well-being and better epidemiological outcomes for thyroid cancer in subsequent generations.
Journal
|
BRAF (B-raf proto-oncogene)
|
BRAF V600E • BRAF V600
8d
Molecular profiling of thyroid nodules on cytologic samples: Findings from an Italian multi-institutional cohort. (PubMed, Cancer Cytopathol)
The Myriapod NGS panel aids in the preoperative assessment of thyroid nodules. Its high negative predictive value may help avoid unnecessary surgery, whereas the detection of specific mutations strongly correlates with malignancy, thus informing surgical planning.
Retrospective data • Journal
|
BRAF (B-raf proto-oncogene)
|
BRAF V600E • BRAF V600